Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 37 people in total across two main groups (called cohorts) and nine smaller dose-level subgroups. Three people took part at each of seven increasing dose levels in Cohort 1, while 3 people started at one dose level and 13 at another in Cohort 2. All 37 participants who started the trial were recorded as having completed it. The trial was testing an experimental virus-based treatment for ovarian cancer, and was primarily designed to find the highest dose that could be given without causing serious side effects — a step commonly taken early in the development of a new treatment. The reported data shows that, for the primary measure — whether participants experienced what are called "dose limiting toxicities" (serious side effects severe enough to stop dose increases) — zero participants in either cohort had such an event. For the secondary measure looking at how tumours responded, the reported data shows that no participants in either cohort had a complete response (tumour disappearing entirely) or a partial response (tumour shrinking by 30% or more). Stable disease (tumour neither growing nor shrinking enough to count as either response or progression) was reported for 14 participants in Cohort 1 and 13 in Cohort 2, while progressive disease (tumour growing) was reported for 7 in Cohort 1 and 3 in Cohort 2. The reported data also tracked a blood marker called CA-125, which can be associated with ovarian cancer, measuring the change from the start of the trial to the last recorded value. Changes varied widely across dose groups, ranging from a decrease of 112 units per millilitre to an increase of 1,200 units per millilitre, depending on the group. The median time until disease progression was reported as 55 days for Cohort 1 and 64.5 days for Cohort 2. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 1 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 or older.
- People who have ovarian cancer or primary peritoneal cancer that has come back, continued to grow, or not gone away after being treated with platinum-based and taxol-based chemotherapy drugs, with the original tumour confirmed by laboratory tissue testing, and who have had both ovaries surgically removed.
- People whose cancer is one of these specific types under the microscope: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's tumour, or adenocarcinoma NOS.
- People whose recent blood test results (taken within 7 days before registering) show healthy enough levels of white blood cells, platelets, liver enzymes, bilirubin, creatinine, and haemoglobin (confirm specific numbers with the trial site).
- People who are able to give informed consent to participate.
- People who are willing to return to Mayo Clinic Rochester for follow-up visits.
- People who are expected to live for at least 12 weeks or more.
- People whose blood tests show they have immunity to measles, at a level of at least 20.0 EU/ml on a specific measles antibody test.
- People who have normal CEA blood levels (below 5 mg/ml) both at the time of joining and in any previous tests — note: this does not apply to one specific group in the trial called the MV-NIS group (confirm with trial site).
- People who are willing to provide all biological samples required by the trial.
- People who have disease that can be measured on physical examination or CT scan — or, for those with elevated CA-125 or very small remaining disease not visible on scans, people who are willing to undergo a keyhole surgical procedure (laparoscopy) to check treatment effects if scans don't show growth after 6 treatment cycles.
- People whose CD4 immune cell count is at least 200/μL, or makes up at least 15% of their lymphocyte blood cells.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose ovarian tumour is classified as low malignant potential (borderline), or is a stromal or germ cell tumour type.
- People for whom a standard treatment exists that is considered potentially curative or likely to meaningfully extend their life — this also includes people experiencing their first relapse if that relapse happened more than 6 months after completing their primary chemotherapy.
- People with a low general health and activity level, rated 3 or 4 on a standard medical performance scale (meaning significantly limited in daily activity or fully disabled).
- People who have had an active infection within 5 days before registering.
- People with a history of tuberculosis or a history of a positive tuberculosis skin test (PPD test).
- People who have had another cancer within the past 5 years, except for non-melanoma skin cancer or very early-stage cervical cancer (carcinoma in situ).
- People who have recently had certain treatments, including: chemotherapy within the last 3 weeks; immunotherapy or biological therapy within the last 4 weeks; major abdominal surgery involving the bowel within the last 3 weeks (note: port placement or scar tissue removal at the time of trial entry is not excluded); or any prior viral or gene therapy at any time.
- People who have not fully recovered from the side effects of previous chemotherapy, regardless of how long ago it was given.
- People with significant heart conditions, including serious heart failure (New York Heart Association class III or IV), known or symptomatic coronary artery disease, or known heart rhythm problems such as atrial fibrillation or SVT.
- People who currently need blood transfusions or blood product support.
- People who have cancer that has spread to the brain, or who have a seizure disorder.
- People who have tested positive for HIV, or who have any other condition causing a weakened immune system.
- People who have had an organ transplant.
- People with a history of chronic hepatitis B or C infection.
- People currently receiving other chemotherapy, immunotherapy, radiation therapy, or any other experimental treatment.
- People taking any other medications that could interfere with how the trial treatment works (confirm with trial site).
- People who have disease larger than 8 cm inside the abdomen, disease that has spread into the liver tissue itself, or disease that has spread outside the abdominal area.
- People taking oral or systemic steroid medications — topical creams or inhaled steroids are not excluded.
- People who live with children under 15 months old, or who live with anyone who has a known weakened immune system.
- People who are allergic to the measles vaccine, or who have had a severe reaction to a measles vaccination in the past.
- People who are allergic to iodine — note: this does not include reactions to intravenous contrast dye used in scans.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Dose Limiting Toxicity
Other options
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.